Fiscal 2021 Fourth Quarter Highlights Net sales of $76.8 million increased 31.7% compared to the prior-year quarter Gross margin of 55.1% increased 330 basis points year over year GAAP loss per share of $0.51 , inclusive of a $14.0 million write-off of OARTrac intangible assets, and adjusted

LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 8, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will host its Investor & Technology Day on Tuesday, July 13

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 24, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and

Company to Hold Fiscal Fourth Quarter and Fiscal Year 2021 Earnings Conference Call and Virtual Investor and Technology Day on July 13, 2021 LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 8, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for

LATHAM, N.Y. --(BUSINESS WIRE)--May 17, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, will

Thrombectomy Device with Off-Circuit Mechanical Aspiration Design for Treatment of Undesirable Intravascular Material in Venous System and Peripheral Vasculature LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 12, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 5, 2021-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

Fiscal 2021 Third Quarter Highlights Net sales of $71.2 million increased 2.0% compared to the prior-year quarter Gross margin of 54.1%, a decline of 370 basis points year over year GAAP loss per share of $0.09 and adjusted earnings per share of $0.02 Cash and cash equivalents on February 28, 2021

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 15, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 9, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 9, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 1, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 1, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Richard C.

Fiscal 2021 Second Quarter Highlights Net sales of $72.8 million increased 4.0% compared to the prior-year quarter Gross margin declined 410 basis points year over year to 55.2% GAAP loss per share of $0.11 and adjusted earnings per share of $0.01 Cash and cash equivalents on November 30, 2020 were

LATHAM, N.Y. --(BUSINESS WIRE)--Jan. 4, 2021-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 29, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 9, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of

Represents Largest Catheter Based Thromboaspiration Study Completed to Date LATHAM, N.Y. --(BUSINESS WIRE)--Nov. 12, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology,

Fiscal 2021 First Quarter Highlights Net sales of $70.2 million increased 6.3% compared to the prior-year quarter, inclusive of the previously disclosed $5.2 million order from the National Health Service ( NHS ) in the UK Gross margin declined 700 basis points year over year to 50.9% GAAP loss per

ADVANCED MEDICAL TECHNOLOGY SAFELY 1 & EFFECTIVELY TREATS PAD, CLI, ISR LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 21, 2020-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today